The development and deployment of new vaccines, particularly for malaria and COVID-19, are the focus of recent discussions. Princeton's Peter Singer and Zacharia Kafuko emphasize the potential of a new low-cost malaria vaccine to save lives, with Singer questioning the prioritization of regulatory processes for such vaccines. Tokyo's Meiji Seika Pharma has also received approval for its Kostaive sa-mRNA COVID-19 vaccine, addressing global health concerns. Calls to accelerate the distribution of malaria vaccines, especially in sub-Saharan Africa, are being made to address the significant number of deaths among children due to malaria.
When vaccines for COVID-19 first became available, governments’ highest priority was to get them through the regulatory process. Will the same be true of R21/Matrix-M, a new, low-cost malaria vaccine? asks @Princeton's @PeterSinger. https://t.co/6rZXO4MSrW
Given the staggering scale of deaths of children in sub-Saharan Africa every year to malaria, shouldn’t we also be treating malaria vaccine deployment as an emergency? Zacharia Kafuko writes. https://t.co/Um1MFtlIuz
Accelerate the distribution of malaria vaccines! https://t.co/j6B8BhfwtA
Tokyo's Meiji Seika Pharma Unveils Kostaive: A Game-Changing, Self-Amplifying COVID-19 Vaccine Amidst Rising Global Health Fears Tokyo's Meiji Seika Pharma has just received the green light for the production and marketing of its Kostaive sa-mRNA COVID-19 vaccine, as revealed in… https://t.co/29DDVtXWni
Emergency deployment of new malaria vaccines could save tens of thousands of children, Zacharia Kafuko writes. https://t.co/Um1MFtlIuz
Even when judged by global, rather than American, standards, saving a life for $3,300 is exceptionally good value. And now it's possible, thanks to a new malaria vaccine, writes @Princeton's @PeterSinger. https://t.co/a2E94n85cV